The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable
Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is
to evaluate the safety, pharmacokinetics and efficacy of FB2001 in patients with moderate to
severe COVID-19 disease.